In a regulatory filing, Gingko Bioworks (DNA) said it is aware of the closure of Silicon Valley Bank (SIVB) and appointment of the Federal Deposit Insurance Corporation as receiver. Only the cash balance of the company’s wholly-owned subsidiary Zymergen Inc. is held in deposit accounts at SVB, representing approximately $74M or 6% of the company’s cash and cash equivalents as of December 31, 2022. The company does not maintain any other material accounts or lines of credit with SVB.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks price target lowered to $3 from $4 at BTIG
- Ginkgo Bioworks sees 2023 revenue at least $275M, consensus $381.51M
- Ginkgo Bioworks reports Q4 EPS (10c), consensus (21c)
- Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
- Ginkgo Bioworks options imply 10.1% move in share price post-earnings